tiprankstipranks
Trending News
More News >

IGM Biosciences Announces Merger with Concentra Biosciences

Story Highlights
IGM Biosciences Announces Merger with Concentra Biosciences

Don’t Miss TipRanks’ Half-Year Sale

IGM Biosciences ( (IGMS) ) just unveiled an announcement.

On July 1, 2025, IGM Biosciences announced a merger agreement with Concentra Biosciences, where Concentra will acquire IGM Biosciences for $1.247 per share in cash, plus a contingent value right. The transaction, expected to close in August 2025, is subject to conditions including a tender offer for outstanding shares and a minimum cash requirement. The merger aims to benefit IGM Biosciences’ stockholders and positions the company as a wholly owned subsidiary of Concentra.

The most recent analyst rating on (IGMS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on IGM Biosciences stock, see the IGMS Stock Forecast page.

Spark’s Take on IGMS Stock

According to Spark, TipRanks’ AI Analyst, IGMS is a Underperform.

IGM Biosciences’ overall stock score reflects major financial and operational challenges, highlighted by negative corporate events and bearish technical indicators. While valuation offers slight neutrality, the financial instability and compliance risks underpin a low score.

To see Spark’s full report on IGMS stock, click here.

More about IGM Biosciences

IGM Biosciences is a biotechnology company focused on developing engineered IgM-based therapeutic antibodies.

Average Trading Volume: 211,669

Technical Sentiment Signal: Sell

Current Market Cap: $64.92M

Learn more about IGMS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1